Investigational New Drugs

, Volume 36, Issue 2, pp 230–239 | Cite as

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

  • Giovanna Speranza
  • Larry Anderson
  • Alice P. Chen
  • Khanh Do
  • Michelle Eugeni
  • Marcie Weil
  • Larry Rubinstein
  • Eva Majerova
  • Jerry Collins
  • Yvonne Horneffer
  • Lamin Juwara
  • Jennifer Zlott
  • Rachel Bishop
  • Barbara A. Conley
  • Howard Streicher
  • Joseph Tomaszewski
  • James H. Doroshow
  • Shivaani Kummar
PHASE I STUDIES
  • 185 Downloads

Summary

Background Molecular chaperone targeting has shown promise as a therapeutic approach in human cancers of various histologies and genetic backgrounds. The purine-scaffold inhibitor PU-H71 (NSC 750424), selective for Hsp90 in epichaperome networks, has demonstrated antitumor activity in multiple preclinical cancer models. The present study was a first in-human trial of PU-H71 aimed at establishing its safety and tolerability and characterizing its pharmacokinetic (PK) profile on a weekly administration schedule in human subjects with solid tumors refractory to standard treatments. Methods PU-H71 was administered intravenously over 1 h on days 1 and 8 of 21-day cycles in patients with refractory solid tumors. Dose escalation followed a modified accelerated design. Blood and urine were collected during cycles 1 and 2 for pharmacokinetics analysis. Results Seventeen patients were enrolled in this trial. Grade 2 and 3 adverse events were observed but no dose limiting toxicities occurred, thus the human maximum tolerated dose was not determined. The mean terminal half-life (T1/2) was 8.4 ± 3.6 h, with no dependency to dose level. A pathway for the metabolic disposal of PU-H71 in humans was derived from microsome studies. Fourteen patients were also evaluable for clinical response; 6 (35%) achieved a best response of stable disease for >2 cycles, with 2 patients remaining on study for 6 cycles. The study closed prematurely due to discontinuation of drug supply. Conclusions PU-H71 was well tolerated at the doses administered during this study (10 to 470 mg/m2/day), with no dose limiting toxicities.

Keywords

Hsp90 Epichaperome PU-H71 Pharmacokinetics Cancer 

Notes

Acknowledgements

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contracts No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The authors thank Dr. Mariam Konaté, Kelly Services, for editorial support in the preparation of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Palotai R, Szalay MS, Csermely P (2008) Chaperones as integrators of cellular networks: changes of cellular integrity in stress and diseases. IUBMB Life 60:10–18CrossRefPubMedGoogle Scholar
  2. 2.
    Taipale M, Tucker G, Peng J, Krykbaeva I, Lin ZY, Larsen B, Choi H, Berger B, Gingras AC, Lindquist S (2014) A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell 158:434–448CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G (2016) The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 538:397–401CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Richter K, Buchner J (2001) Hsp90: chaperoning signal transduction. J Cell Physiol 188:281–290CrossRefPubMedGoogle Scholar
  5. 5.
    Young JC, Moarefi I, Hartl FU (2001) Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154:267–273CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100:1523–1529CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772CrossRefPubMedGoogle Scholar
  8. 8.
    Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G (2014) Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs 23:611–628CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410CrossRefPubMedGoogle Scholar
  10. 10.
    Burrows F, Zhang H, Kamal A (2004) Hsp90 activation and cell cycle regulation. Cell Cycle 3:1530–1536CrossRefPubMedGoogle Scholar
  11. 11.
    Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67:2932–2937CrossRefPubMedGoogle Scholar
  12. 12.
    McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, Kluger HM (2008) HSP90 as a marker of progression in melanoma. Ann Oncol 19:590–594CrossRefPubMedGoogle Scholar
  13. 13.
    Prodromou C, Pearl LH (2003) Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 3:301–323CrossRefPubMedGoogle Scholar
  14. 14.
    Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324–8328CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Usmani SZ, Bona R, Li Z (2009) 17 AAG for HSP90 inhibition in cancer--from bench to bedside. Curr Mol Med 9:654–664CrossRefPubMedGoogle Scholar
  16. 16.
    Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9:1479–1492CrossRefPubMedGoogle Scholar
  17. 17.
    Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46:340–347CrossRefPubMedGoogle Scholar
  18. 18.
    Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP, Belani CP (2010) Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28:1520–1526CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chiosis G (2006) Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 6:1183–1191CrossRefPubMedGoogle Scholar
  20. 20.
    Immormino RM, Kang Y, Chiosis G, Gewirth DT (2006) Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J Med Chem 49:4953–4960CrossRefPubMedGoogle Scholar
  21. 21.
    Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G (2011) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 7:818–826CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E (2013) Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 122:2837–2847CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A (2009) A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 15:1369–1376CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA (2009) Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50:102–112CrossRefPubMedGoogle Scholar
  25. 25.
    Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368–8373CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147CrossRefPubMedGoogle Scholar
  27. 27.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
  28. 28.
    Goetz MP, Toft DO, Ames MM, Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169–1176CrossRefPubMedGoogle Scholar
  29. 29.
    Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang CH, Jiang Q, Xue LQ, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He SQ, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA (2013) Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3:430–443CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Isaacs JS, Xu WP, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213–217CrossRefPubMedGoogle Scholar
  31. 31.
    Trendowski M (2015) PU-H71: an improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacol Res 99:202–216CrossRefPubMedGoogle Scholar
  32. 32.
    Taldone T, Ochiana SO, Patel PD, Chiosis G (2014) Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci 35:48–59CrossRefGoogle Scholar
  33. 33.
    Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239–250CrossRefPubMedGoogle Scholar
  34. 34.
    Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 10:1307–1315CrossRefPubMedGoogle Scholar
  35. 35.
    Miyata Y (2005) Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11:1131–1138CrossRefPubMedGoogle Scholar
  36. 36.
    Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, Mitchell JB (2010) Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med 48:1559–1563CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Siegel D, Yan C, Ross D (2012) NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83:1033–1040CrossRefPubMedGoogle Scholar
  38. 38.
    Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64–76CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202–216CrossRefPubMedGoogle Scholar
  40. 40.
    Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78:626–630CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Lin TY, Bear M, Du ZJ, Foley KP, Ying WW, Barsoum J, London C (2008) The novel HSP90 inhibitor STA-9090 exhibits activity against kit-dependent and -independent malignant mast cell tumors. Exp Hematol 36:1266–1277CrossRefPubMedGoogle Scholar
  42. 42.
    Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152–161CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S (2014) A phase II open-label study of Ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 14:154–160CrossRefPubMedGoogle Scholar
  44. 44.
    Taldone T, Chiosis G (2009) Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 9:1436–1446CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8:289–299CrossRefPubMedGoogle Scholar
  46. 46.
    Chiosis G, Kang Y, Sun W (2008) Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opin Drug Discov 3:99–114CrossRefPubMedGoogle Scholar
  47. 47.
    Gallerne C, Prola A, Lemaire C (2013) Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta 1833:1356–1366CrossRefPubMedGoogle Scholar
  48. 48.
    Qu Z, Wang S, Teng R, Yi X (2014) PU-H71 effectively induces degradation of IkappaB kinase beta in the presence of TNF-alpha. Mol Cell Biochem 386:135–142CrossRefPubMedGoogle Scholar
  49. 49.
    Segawa T, Fujii Y, Tanaka A, Bando S, Okayasu R, Ohnishi K, Kubota N (2014) Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med 33:559–564CrossRefPubMedGoogle Scholar
  50. 50.
    Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NVK (2016) Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. J Labelled Comp Radiopharm 59:129–132CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, DaGama EG, Uddin M, Chiosis G, Lewis JS, Lyashchenko SK, Larson SM, Pressl C, Dunphy M (2015) Phase I trial of the HSP-90 inhibitor PU-H71. J Clin Oncol 33:2537–2537CrossRefGoogle Scholar

Copyright information

© US Government (outside the USA) 2017

Authors and Affiliations

  • Giovanna Speranza
    • 1
  • Larry Anderson
    • 1
  • Alice P. Chen
    • 1
  • Khanh Do
    • 1
  • Michelle Eugeni
    • 1
  • Marcie Weil
    • 1
  • Larry Rubinstein
    • 1
  • Eva Majerova
    • 2
  • Jerry Collins
    • 1
  • Yvonne Horneffer
    • 1
  • Lamin Juwara
    • 2
  • Jennifer Zlott
    • 1
  • Rachel Bishop
    • 3
  • Barbara A. Conley
    • 1
  • Howard Streicher
    • 1
  • Joseph Tomaszewski
    • 1
  • James H. Doroshow
    • 1
  • Shivaani Kummar
    • 1
    • 4
  1. 1.Division of Cancer Treatment and Diagnosis, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Leidos Biomedical Research, Inc.Frederick National Laboratory for Cancer ResearchFrederickUSA
  3. 3.National Eye InstituteNational Institutes of HealthBethesdaUSA
  4. 4.Stanford University School of MedicinePalo AltoUSA

Personalised recommendations